Should I buy or sell Smith & Nephew stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares. View SNN analyst ratings or view top-rated stocks .

How have SNN shares performed in 2024?

Smith & Nephew's stock was trading at $27.28 at the beginning of 2024. Since then, SNN stock has decreased by 12.0% and is now trading at $24.0050. View the best growth stocks for 2024 here .

Are investors shorting Smith & Nephew?

Smith & Nephew saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,980,000 shares, a decrease of 17.5% from the March 15th total of 2,400,000 shares. Based on an average daily volume of 972,300 shares, the short-interest ratio is presently 2.0 days. Currently, 0.5% of the company's shares are short sold. View Smith & Nephew's Short Interest .

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a semi-annual dividend on Monday, March 4th. Stockholders of record on Tuesday, April 2nd will be given a dividend of $0.462 per share on Wednesday, May 22nd. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, April 1st. Read our dividend analysis for SNN .

Is Smith & Nephew a good dividend stock?

Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.90 per share and currently has a dividend yield of 3.78%. Read our dividend analysis for SNN .

What ETFs hold Smith & Nephew's stock?

ETFs with the largest weight of Smith & Nephew (NYSE:SNN) stock in their portfolio include ALPS Disruptive Technologies ETF (DTEC) . iShares Frontier and Select EM ETF (FM) .

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN) , RPM International (RPM) , Gilead Sciences (GILD) , AbbVie (ABBV) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , Pfizer (PFE) , Abbott Laboratories (ABT) , Alexion Pharmaceuticals (ALXN) and Amgen (AMGN) .

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scharf Investments LLC (0.69%), Ridgewood Investments LLC (0.02%), Curbstone Financial Management Corp (0.00%), BKM Wealth Management LLC (0.00%), Park Avenue Securities LLC (0.00%) and Marotta Asset Management (0.00%).

How do I buy shares of Smith & Nephew?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:SNN

Smith & Nephew (SNN) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free SNN Stock Alerts

$23.98

-0.03 (-0.12%)

(As of 09:56 AM ET)

Compare

Today's Range: $23.90
▼
$23.98
50-Day Range: $23.78
▼
$28.88
52-Week Range: $21.52
▼
$33.08

Volume: 43,999 shs
Average Volume: 955,135 shs
Market Capitalization: $10.48 billion

P/E Ratio: N/A
Dividend Yield: 3.75%
Price Target: N/A

Get Smith & Nephew alerts:

Smith & Nephew MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.46% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.86
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 17.51%
From $1.77 to $2.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.87 out of 5 stars

Medical Sector

352nd out of 918 stocks

Surgical Appliances & Supplies Industry

12th out of 18 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Smith & Nephew.

5.0

Short Interest

Percentage of Shares Shorted
0.46% of the float of Smith & Nephew has been sold short.
Short Interest Ratio / Days to Cover
Smith & Nephew has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Smith & Nephew has recently decreased by 17.50%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Leadership
Smith & Nephew is a leading dividend payer. It pays a dividend yield of 3.78%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Smith & Nephew has only been increasing its dividend for 1 years.
Dividend Sustainability
Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 43.27% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNN.

3.3

News and Social Media Coverage

News Sentiment
Smith & Nephew has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Smith & Nephew this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for SNN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Smith & Nephew insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Smith & Nephew is held by insiders.
Percentage Held by Institutions
Only 25.64% of the stock of Smith & Nephew is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Smith & Nephew are expected to grow by 17.51% in the coming year, from $1.77 to $2.08 per share.
Price to Earnings Growth Ratio
Smith & Nephew has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Smith & Nephew has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Smith & Nephew Stock (NYSE:SNN)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

SNN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNN Stock News Headlines

April 18, 2024 | finanznachrichten.de

Smith & Nephew UK Ltd: Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing's role in pressure injury prevention

April 18, 2024 | markets.businessinsider.com

Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 18, 2024 | finance.yahoo.com

Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention

April 15, 2024 | americanbankingnews.com

Short Interest in Smith & Nephew plc (NYSE:SNN) Declines By 17.5%

April 8, 2024 | globenewswire.com

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

April 4, 2024 | finance.yahoo.com

Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)

April 4, 2024 | globenewswire.com

Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 2, 2024 | msn.com

Smith+Nephew launches wound therapy system in US

April 1, 2024 | globenewswire.com

Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds

March 28, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday

March 28, 2024 | lse.co.uk

Smith & Nephew CFO designate John Rogers to start next week

March 28, 2024 | marketwatch.com

Smith & Nephew: John Rogers Appointed CFO

March 28, 2024 | finanznachrichten.de

Smith+Nephew: John Rogers To Join Board As Executive Director And CFO On 1 April

March 25, 2024 | msn.com

Medical supplies firm Smith & Nephew teams up with mixed martial arts promoter the UFC

March 25, 2024 | globenewswire.com

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner

February 28, 2024 | seekingalpha.com

Smith & Nephew plc 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | msn.com

Smith & Nephew reports Q4 results

February 21, 2024 | investorplace.com

3 Millionaire-Maker Robotics Stocks to Buy in February 2024

February 12, 2024 | msn.com

Smith&Nephew Dips on Expanding Sports Medicine Lineup

January 18, 2024 | realmoney.thestreet.com

Smith & Nephew price target lowered by 50 GBp at Berenberg

January 10, 2024 | thetimes.co.uk

Smith & Nephew hopes $330m CartiHeal deal is a leg-up

November 14, 2023 | finance.yahoo.com

After losing 1.8% in the past year, Smith & Nephew plc (LON:SN.) institutional owners must be relieved by the recent gain

November 10, 2023 | lse.co.uk

LONDON BROKER RATINGS: Goldman likes Smith & Nephew; UBS picks Wise

November 5, 2023 | seekingalpha.com

Smith & Nephew plc 2023 Q3 - Results - Earnings Call Presentation

November 4, 2023 | markets.businessinsider.com

Hold Rating on Smith & Nephew Snats: Growth Amid Challenges and Expectations for Future Improvements

See More Headlines

Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/17/2014
Ex-Dividend for 5/22 Dividend: 4/01/2024
Today: 4/19/2024
Dividend Payable: 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NYSE:SNN
CUSIP: N/A
CIK: 845982
Web: www.smith-nephew.com
Phone: 441923477100
Fax: 44-20-7930-3353
Employees: 18,452
Year Founded: 1856

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.56
P/E Growth: 1.29
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.44
Current Ratio: 1.77
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: $5.55 billion
Price / Sales: 1.89
Cash Flow: $3.23 per share
Price / Cash Flow: 7.44
Book Value: $11.94 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 437,160,000
Free Float: 432,788,000
Market Cap: $10.49 billion
Optionable: Optionable
Beta: 0.73

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Deepak S. Nath Ph.D. (Age 52)
CEO & Director
Comp: $4.66M
Ms. Anne-Francoise Nesmes (Age 53)
CFO & Executive Director
Comp: $1.91M
Mr. Paul Connolly (Age 56)
President of Global Operations
Mr. Andrew Swift
Vice President of Investor Relations
Ms. Helen Barraclough (Age 45)
Group General Counsel & Company Secretary
Ms. Alison Parkes (Age 52)
Chief Compliance Officer & Compliance APAC
Mr. Joe Metzger
Senior Vice President of Marketing Services & Communications
Mr. Philip G. Cowdy (Age 57)
Chief Corporate Development & Corporate Affairs Officer
Ms. Elga Lohler (Age 56)
Chief Human Resources Officer
Dr. Vasant Padmanabhan Ph.D. (Age 57)
President of Research & Development and Ear, Nose & Throat

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View SNN analyst ratings or view top-rated stocks.
How have SNN shares performed in 2024?: Smith & Nephew's stock was trading at $27.28 at the beginning of 2024. Since then, SNN stock has decreased by 12.0% and is now trading at $24.0050.
View the best growth stocks for 2024 here.
Are investors shorting Smith & Nephew?: Smith & Nephew saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,980,000 shares, a decrease of 17.5% from the March 15th total of 2,400,000 shares. Based on an average daily volume of 972,300 shares, the short-interest ratio is presently 2.0 days. Currently, 0.5% of the company's shares are short sold.
View Smith & Nephew's Short Interest.
How were Smith & Nephew's earnings last quarter?: Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?: Smith & Nephew declared a semi-annual dividend on Monday, March 4th. Stockholders of record on Tuesday, April 2nd will be given a dividend of $0.462 per share on Wednesday, May 22nd. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, April 1st.
Read our dividend analysis for SNN.
Is Smith & Nephew a good dividend stock?: Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.90 per share and currently has a dividend yield of 3.78%.
Read our dividend analysis for SNN.

What ETFs hold Smith & Nephew's stock?: ETFs with the largest weight of Smith & Nephew (NYSE:SNN) stock in their portfolio include ALPS Disruptive Technologies ETF (DTEC).iShares Frontier and Select EM ETF (FM).
What other stocks do shareholders of Smith & Nephew own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).
Who are Smith & Nephew's major shareholders?: Smith & Nephew's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scharf Investments LLC (0.69%), Ridgewood Investments LLC (0.02%), Curbstone Financial Management Corp (0.00%), BKM Wealth Management LLC (0.00%), Park Avenue Securities LLC (0.00%) and Marotta Asset Management (0.00%).
How do I buy shares of Smith & Nephew?: Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:SNN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial